SEARCH:   Advanced

Blood, 1 April 2008, Vol. 111, No. 7, pp. 3439-3441. Prepublished online as a Blood First Edition Paper on January 14, 2008; DOI 10.1182/blood-2007-09-112052. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-09-112052v1 111/7/3439    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bonig, H. Articles by Papayannopoulou, T. Search for Related Content PubMed PubMed Citation Articles by Bonig, H. Articles by Papayannopoulou, T. Related Collections Hematopoiesis and Stem Cells Transplantation Brief Reports Clinical Trials and Observations Related Articles in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMATOPOIESIS AND STEM CELLS Brief Report Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab Halvard Bonig1, Annette Wundes2, Kai-Hsin Chang1, Sylvia Lucas3, and Thalia Papayannopoulou1 Departments of1 Medicine/Hematology, 2 Rehabilitation Medicine, and 3 Neurology, University of Washington, Seattle Blockade of CD49d-mediated lymphocyte trafficking has been used therapeutically for certain autoimmune diseases, such as multiple sclerosis (MS). In addition to negative effects on the trafficking of mature lymphocytes to sites of inflammation, CD49d blockade in mice and monkeys rapidly mobilizes hematopoietic stem/progenitor cells (HSPCs) capable of short- and long-term engraftment. Here we aimed to ascertain the effects of treatment with antifunctional anti-CD49d antibody in humans (MS patients receiving infusions of the CD49d-blocking antibody natalizumab) on levels of circulating HSPCs after a single dose of antibody or after long-term treatment. On average, 6-fold elevated levels of circulating CD34+ cells and colony-forming unit-culture (CFU-C) were achieved within 1 day of the first dose of natalizumab, and similar levels were continuously maintained under monthly natalizumab infusions. The blood of natalizumab-treated subjects also contained SCID-repopulating cells. The fate of these circulating HSPCs and their clinical relevance for MS patients remains to be determined. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Articles in Blood Online: About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Carine Vuaillat, Géraldine Androdias, Nathalie Davoust, and Serge Nataf Blood 2008 112: 208-209. [Full Text] [PDF] Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Halvard Bonig, Annette Wundes, and Thalia Papayannopoulou Blood 2008 112: 209-210. [Full Text] [PDF] This article has been cited by other articles: E. O. Major Reemergence of PML in Natalizumab-Treated Patients -- New Cases, Same Concerns N. Engl. J. Med., September 10, 2009; 361(11): 1041 - 1043. [Full Text] [PDF] D. Soler, T. Chapman, L.-L. Yang, T. Wyant, R. Egan, and E. R. Fedyk The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 864 - 875. [Abstract] [Full Text] [PDF] P. Ramirez, M. P. Rettig, G. L. Uy, E. Deych, M. S. Holt, J. K. Ritchey, and J. F. DiPersio BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells Blood, August 13, 2009; 114(7): 1340 - 1343. [Abstract] [Full Text] [PDF] C. N. Abboud Another nail in the AML coffin Blood, June 11, 2009; 113(24): 6045 - 6046. [Full Text] [PDF] K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project Blood, May 14, 2009; 113(20): 4834 - 4840. [Abstract] [Full Text] [PDF] A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting Blood, May 7, 2009; 113(19): 4604 - 4613. [Abstract] [Full Text] [PDF] H. Wiendl and R. Hohlfeld Multiple sclerosis therapeutics: Unexpected outcomes clouding undisputed successes Neurology, March 17, 2009; 72(11): 1008 - 1015. [Abstract] [Full Text] [PDF] M. Krumbholz, I. Meinl, T. Kumpfel, R. Hohlfeld, and E. Meinl Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis Neurology, October 21, 2008; 71(17): 1350 - 1354. [Abstract] [Full Text] [PDF] J. D. Isaacs Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future Rheumatology, October 1, 2008; 47(10): 1461 - 1468. [Abstract] [Full Text] [PDF] C. Vuaillat, G. Androdias, N. Davoust, and S. Nataf About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Blood, July 1, 2008; 112(1): 208 - 209. [Full Text] [PDF] H. Bonig, A. Wundes, and T. Papayannopoulou Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors Blood, July 1, 2008; 112(1): 209 - 210. [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020